The present study aimed at evaluating the efficacy of abatacept (ABA) compared to tocilizumab (TCZ), assumed as a gold standard biologic treatment in the management of patients with giant cell arteritis (GCA).

An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis

Rossi, Daniela
First
;
Cecchi, Irene;Sciascia, Savino;Naretto, Carla;Alpa, Mirella;Roccatello, Dario
Last
2021

Abstract

The present study aimed at evaluating the efficacy of abatacept (ABA) compared to tocilizumab (TCZ), assumed as a gold standard biologic treatment in the management of patients with giant cell arteritis (GCA).
39 Suppl 129
2
125
128
Abatacept; Antibodies, Monoclonal, Humanized; Humans; Treatment Outcome; Giant Cell Arteritis
Rossi, Daniela; Cecchi, Irene; Sciascia, Savino; Naretto, Carla; Alpa, Mirella; Roccatello, Dario
File in questo prodotto:
File Dimensione Formato  
article.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 991.64 kB
Formato Adobe PDF
991.64 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1796182
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 0
social impact